Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Chronic plantar fasciitis (duration of disorder at least 4 months)

• At least 4 points on the visual analogue scale (0-10) for the most severe pain within the last 48 hours

• At least 2 previous unsuccessful conservative therapies

• Age 18 and older

Exclusion Criteria:

• Rheumatoid diseases (M. Bechterew, chronic polyarthritis, psoriasis-arthritis, para /post-infectious arthritis etc.)

• Previous surgery in the affected area of the foot

• Pre-treatment with Botulinum toxin A (only de novo patients)

• Prohibited concomitant treatment: local injections during the study and 2 weeks prior to start of study